Dr. Park on Updates With CAR T Cells in ALL

Video

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

Jae H. Park, MD, attending physician, Leukemia Service and Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia (ALL).

Initial data with CAR T-cell therapy showed a complete response rate of approximately 80% in pediatric and adult patients with relapsed/refractory ALL, says Park. Although approximately 40% of patients will relapse early, some patients can experience durable responses lasting 3 to 5 years.

Ongoing research is evaluating which patients will benefit the most from this strategy, explains Park. The goal is to minimize toxicity and improve remission durations while retaining efficacy. To date, patients with lower disease burden appear to derive the greatest benefit from CAR T-cell therapy.

Ongoing trials are exploring additional targets with the goal of minimizing, and ultimately eliminating, toxicity, concludes Park.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.